Oncology is increasingly shifting from broad-spectrum therapeutics to precision medicine strategies in an effort to create safer, more effective drugs. By tailoring treatments to the unique features of a patient’s tumor, researchers aim to exploit vulnerabilities that are invisible to traditional approaches. One compelling example of this principle at work is synthetic lethality, where specific mutation-driven weaknesses in cancer cells can be selectively targeted, allowing for precise and highly effective cell killing.
While traditional drug discovery has focused on targeting gain-of-function mutations, synthetic lethality instead exploits vulnerabilities created by loss-of-function mutations, which often render cancer cells unusually dependent on certain proteins and pathways. Altered metabolic states in these cells also create an opportunity to design drugs that target the tumor’s unique biochemical environment, increasing specificity and sparing healthy tissue.
In these systems, traditional competitive inhibitors can struggle to overcome the high levels of metabolites found in tumor cells, and their binding may be less effective in the tumor environment than in healthy tissue. As a result, researchers are exploring alternative drug classes, such as uncompetitive and cooperative inhibitors, which work with the tumor microenvironment rather than against it.
As drug mechanisms grow more complex, it is imperative to validate them in physiologically relevant systems. The tools we use to study these mechanisms must evolve to generate biologically meaningful data that directly links binding to cellular outcomes.
Metabolite-driven selectivity
Uncompetitive inhibition provides a new way to target tumor cells with specific metabolic states. Instead of competing with high metabolite levels for access to the target, these inhibitors bind only after the enzyme has engaged its substrate. This effectively links drug activity to the metabolic state of the cell. In tumor cells with altered metabolism, where these enzyme-substrate complexes are more abundant or stable, uncompetitive inhibition can achieve a level of selectivity that competitive inhibitors struggle to match.
One emerging example is the selective inhibition of the methyltransferase PRMT5 (protein arginine methyltransferase 5). This protein typically binds the metabolite SAM (s-adenosyl methionine) to support gene expression, RNA splicing, and cell signaling. However, in a subset of cancers, the loss of the MTAP (methylthioadenosine phosphorylase) gene leads to the accumulation of the metabolite MTA. MTA competes with SAM and partially blocks PRMT5, weakening its activity. This makes the cancer cells uniquely dependent on the remaining PRMT5 function, creating a metabolic vulnerability. Drugs that inhibit PRMT5 in this context can selectively kill these cancer cells while leaving healthy cells largely unharmed.
Earlier generations of PRMT5 inhibitors struggled to achieve selectivity in this context because they either directly compete with the metabolite pocket or bind less favorably under high-MTA conditions. In contrast, MTA-uncompetitive chemotypes are designed to engage PRMT5 specifically under high-MTA conditions. However, these compounds are hard to identify and study because their biochemical potency does not always predict how well they kill cancer cells or spare healthy ones in MTAP-deleted models.
To characterize this type of inhibitor, we need tools that capture the dynamic regulation of metabolite concentrations, protein complexes and enzyme states.
Limits of biochemical and functional assays
Inhibitor mechanisms are often inferred from biochemical assays or downstream functional readouts, such as cell viability. These assays are valuable tools for drug discovery, but they have significant limitations.
Biochemical assays can reveal how a drug interacts with its target, but they miss many important factors present in cells. Protein-protein interactions, post-translational modifications, and metabolite levels can all influence whether a target is truly vulnerable. As a result, biochemical assays often fail to predict cellular response, particularly when target vulnerability varies across cell lines.
Functional assays can demonstrate biological relevance but fail to provide a clear picture of the drug mechanism. Without directly measuring target engagement, it’s impossible to know if a cell’s sensitivity comes from on-target activity or off-target effects. This approach creates significant blind spots that can only be mitigated by studying target engagement in live cells.
Live-cell target engagement assays, including luminescence- and resonance energy transfer-based approaches, bridge the gap between biochemical and functional assays by evaluating a target protein in its native cellular context. In these assays, drug–target engagement is measured directly in intact, metabolically active cells, rather than inferred from downstream functional effects. As a result, the binding potencies they reveal often align closely with actual cellular responses. They also show not just whether a compound binds its target, but under what cellular conditions this binding occurs. This information is especially important for understanding drug activity in disease states, particularly when selectivity depends on differences in cellular metabolism.
Characterizing uncompetitive binding with live-cell assays
In a recent paper published in Nature Communications, researchers at Promega demonstrated an approach for quantifying target engagement that is dependent on metabolic context, enabling the development of selective uncompetitive inhibitors.
With collaborators at the University of Oxford and the State University of New York at Stony Brook, Promega researchers developed a live-cell NanoBRET target engagement assay, based on bioluminescence resonance energy transfer, that enables quantitative measurement of PRMT5 target engagement in intact cells across all major PRMT5 drug classes, including MTA-uncompetitive compounds.
The assay uses a cell-permeable probe called a tracer, which binds to the target protein and can be displaced by the test compound. This tracer is unique in that it is sensitive to intracellular SAM/MTA ratios, meaning that changes in its binding provide both a measure of compound potency and a readout of the cell’s metabolite state.
Using this system, live-cell binding potencies were evaluated for multiple classes of PRMT5 inhibitors under different SAM/MTA ratios, and in a disease-relevant MTAP-deleted cell line. MTA-uncompetitive compounds were clearly distinguished from early-generation PRMT5 inhibitors, and their differential affinities were shown to be governed by intracellular MTA levels.
This data directly links genetic context, metabolic state, and drug mechanism in a way that was not previously possible. More broadly, the approach provides a way for researchers to identify and screen for drugs that require context-dependent engagement in a more physiologically relevant setting.
Implications for drug discovery
This study expands the ability to evaluate drug selectivity under physiologically relevant conditions. It is no longer sufficient to ask only whether a compound binds its target; the cellular conditions under which that engagement occurs must also be considered. This distinction is critical for precision oncology strategies built on synthetic lethality. Direct measurement of target engagement in live cells allows phenotypic responses to be linked to on-target drug activity, providing a more accurate picture of compound efficacy and enhancing the development of precision medicines.
As therapeutic mechanisms become increasingly sophisticated, the tools used to study them must evolve accordingly. Precision oncology depends not only on identifying the right targets but also on understanding how, when, and where drugs engage them. With that goal, the ability to observe mechanisms directly in cells becomes a necessity, not a luxury.
